A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors

NCT ID: NCT07126665

Last Updated: 2025-11-18

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 116 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-18
• Study Completion Date: 2031-08-31

Brief Summary

This is a first-in-human, open-label, multicenter Phase I/II study of MHB088C combined with MHB039A in patients with advanced malignant solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB088C and MHB039A combination therapy.

Detailed Description

This first-in-human clinical trial of MHB088C and MHB039A combination therapy comprises two parts: a dose escalation phase and indication expansion phase. The dose escalation phase is an open-label, multicenter study including dose escalation and PK expansion cohorts. The primary objectives are to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MHB088C combined with MHB039A in patients with advanced solid tumors, and to determine the maximum tolerated dose (MTD). Additional patients may be enrolled in the PK expansion part at dose levels that have completed DLT (dose-limiting toxicity) evaluation.

Based on the safety, PK, and preliminary efficacy data from the completed DLT-evaluated dose levels, the sponsor will initiate the indication expansion phase to further evaluate the safety and efficacy of MHB088C and MHB039A combination therapy in patients with specific types of advanced solid tumors.

Conditions

Advanced Malignant Solid Tumor

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose escalation phase: cohort 1

Subjects will receive MHB088C Q2W in combination with MHB039A Q2W by intravenous administration.

Group Type: EXPERIMENTAL

MHB088C for Injection

Intervention Type: DRUG

Intravenous administration

MHB039A for Injection

Intervention Type: DRUG

Intravenous administration

Dose escalation phase: cohort 2

Subjects will receive MHB088C Q2W in combination with MHB039A Q2W by intravenous administration.

Group Type: EXPERIMENTAL

MHB088C for Injection

Intervention Type: DRUG

Intravenous administration

MHB039A for Injection

Intervention Type: DRUG

Intravenous administration

Indication expansion phase: cohort 3

Subjects will receive MHB088C Q2W in combination with MHB039A Q2W by intravenous administration.

Group Type: EXPERIMENTAL

MHB088C for Injection

Intervention Type: DRUG

Intravenous administration

MHB039A for Injection

Intervention Type: DRUG

Intravenous administration

Indication expansion phase: cohort 4

Subjects will receive MHB088C Q2W in combination with MHB039A Q2W by intravenous administration.

Group Type: EXPERIMENTAL

MHB088C for Injection

Intervention Type: DRUG

Intravenous administration

MHB039A for Injection

Intervention Type: DRUG

Intravenous administration

Interventions

MHB088C for Injection

Intravenous administration

Intervention Type: DRUG

MHB039A for Injection

Intravenous administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Voluntarily agrees to participate in the study and signs the informed consent form.

2. Age ≥ 18 years, no restriction on gender.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

4. Estimated life expectancy ≥ 3 months.

5. For the dose escalation stage: Histologically or cytologically confirmed advanced solid tumors that are refractory to standard therapy, intolerant to standard therapy, or have no standard treatment options.

6. For the dose expansion stage: Histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors, not suitable for radical surgery and/or radical concurrent/sequential radiotherapy and chemotherapy.

7. At least one measurable lesion per RECIST v1.1 criteria.

8. Adequate bone marrow reserve and organ function.

9. Eligible participants of childbearing potential (males and females) must agree to take highly reliable contraceptive measures with their partners during the study and within at least 12 weeks after the last dose.

Exclusion Criteria

1. History of ≥2 primary malignancies within 5 years prior to informed consent.

2. Received chemotherapy within 3 weeks, radiotherapy within 4 weeks, or biologic, endocrine, or immunotherapy within 4 weeks before dosing.

3. Medication of other unmarketed investigational drugs or therapies within 4 weeks before dosing.

4. Brain metastases, leptomeningeal disease, brainstem metastases, or spinal cord compression.

5. Underwent major organ surgery (excluding biopsy) or significant trauma within 4 weeks before the first dose of investigational drug or requiring elective surgery during the study.

6. Previous or concurrent gastrointestinal perforation, surgical procedures and wound healing complications, as well as bleeding events.

7. Received intravenous thrombolysis treatment within 2 weeks, except for preventive anticoagulation and antiplatelet therapy.

8. Vaccinated within 4 weeks before dosing.

9. Treated with systemic corticosteroids within 14 days before dosing.

10. Severe lung disease affecting pulmonary function.

11. Active systemic infection requiring treatment within 7 days before dosing.

12. Uncontrolled third-space effusion.

13. Serious cardiovascular or cerebrovascular diseases.

14. Known hypersensitivity or delayed allergic reaction to the investigational product or its components.

15. Drug abuse or other medical/psychiatric condition that may interfere with study participation or results.

16. Known alcohol or drug dependence.

17. Pregnant or breastfeeding women, or individuals planning to conceive.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Minghui Pharmaceutical (Hangzhou) Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Ethics Committee of Shanghai East Hospital

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

VP of R&D

Role: CONTACT

jwshi@minghuipharma.com

86 0571-869632

Facility Contacts

Ethics Committee

Role: primary

siwei_bao@163.com

+86 021-38804518-22198

Other Identifiers

MHB088C-E-102

Identifier Type: -

Identifier Source: org_study_id